Please login to the form below

Not currently logged in


This page shows the latest Balversa news and features for those working in and with pharma, biotech and healthcare.

J&J taps TARIS Biomedical for novel bladder cancer technology

J&J taps TARIS Biomedical for novel bladder cancer technology

J&J has a strong presence in the bladder cancer area, with its targeted bladder cancer drug Balversa (erdafitinib) gaining approval in the US earlier this year. ... With Balversa, a 99-patient study demonstrated a 40% overall response rate, 3% complete

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....